Acne & Blemish ControlYour Source For Acne & Blemish Products

Beam Therapy
Laser therapy makes inroads in the war against fat If fairy tales were written for adult women, it could go like this: you are in the doctor's office when a fairy godmother stands next to you. As slumber, wave a wand around his waist. When you awaken, you have lost inches in recalcitrant areas – stomach, thighs, hips.

Study indicates the potential for dramatic reduction in TomoTherapy (SM) radiotherapy Time Plan Quality Improvement

MADISON, WI – (Marketwire – November 24, 2009) – TomoTherapy Incorporated (NASDAQ: TOMO) announced today that a study published on 11 November 2009 International Journal of Radiation Oncology * Biology * Physics – commonly known as the Red Journal – said TomoTherapy (SM) treatment times could be reduced by up to 66 percent using advanced radiation delivery. Moreover, these techniques were able to improve the quality of the plan by a further reduction of the amount of radiation received by normal tissue.

The study, entitled "Dynamic Jaws and dynamics in helical TomoTherapy Couch" was directed by Dr. Sterzing Florian Department of Radiation Oncology, University Clinic Heidelberg to explore the benefits of advanced TomoTherapy delivery technique. This technique Delivery will have a dynamic collimator can automatically adjust the size of the radiation beam to optimize the dose to the target and spare surrounding healthy tissue. Another key element would be if a patient couch that can be designed to accelerate the processing time for faster movement between target tumors or those areas that do not require high doses of radiation. The study concluded the Heidelberg University Hospital that the combination of these two advances in research they were able to develop treatment plans indicated treatment times shortened considerably and improve the quality of the treatment plan.

"Our experience in treating patients with TomoTherapy led us to believe that the techniques we explored in our research could lead to more accurate and more Fast treatments, "Dr. Sterzing." Although we limited our study to applications of nasopharyngeal cancer, we believe that these techniques would be invaluable in the treatment of cancer throughout the body, particularly cancers of the prostate and those associated with multiple metastases. "

New Treatment System ™ TomoHD equipped for Advanced Delivery Technology
"At the Annual Meeting of the American Society Radiation Oncology (ASTRO) earlier this month debuted the treatment system and demonstrated how TomoHD Advanced Delivery TomoTherapy technology could used in conjunction with this new treatment system, "said Fred Robertson, MD, president and CEO of TomoTherapy." We believe the combination of the platform multipurpose, with the advanced technique of delivery is studying at the University Clinic Heidelberg TomoTherapy will continue to advance patient care. These innovations will enhance our unique form of delivery of rod, and widely considered the gold standard. "

The treatment system will TomoHD commercially available in the second half of 2010 and has been designed to support advanced technology TomoTherapy delivery. Advanced TomoTherapy delivery technique is currently work in progress and not available for sale.

University Clinic Heidelberg is a research partner of TomoTherapy Incorporated. Representatives TomoTherapy are co-authors on the study noted above.

About TomoTherapy Incorporated
TomoTherapy Incorporated develops, markets and sells Solutions Advanced therapy of radiation that can be used to treat a wide variety of cancers, the most common to complex. The ring gantry based TomoTherapy ® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and accuracy, while reducing radiation exposure to surrounding healthy tissue. TomoTherapy suite of solutions include the flagship of · Hi Art ® treatment system, that has been used to deliver more than three million CT-guided, helical intensity modulated radiation therapy (IMRT) treatment fractions, the system TomoHD ™ treatment, designed to allow cancer centers to treat a wider population of patients with a single device, and TomoMobile ™ relocatable radiation therapy solution to improve access and availability of state of the art cancer care. TomoTherapy shares are listed on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

Forward-Looking Statements
The statements in this release regarding future products or product capabilities, events, expectations and other similar matters, including but not limited statements using the words "expects," "should," "could," "Believe (s)," "suggests" or "states" are forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements contained in this release release are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated, including but not limited to factors such as the ability to gain customer acceptance, ability to complete development in a timely manner, the ability to protect intellectual property, risks of interruption due to events beyond the control of the company, and other risks listed from time to time in TomoTherapy submissions to the Securities and Exchange Commission, which by this reference are incorporated in this document. These forward-looking statements represent TomoTherapy judgments as of the date of this press release. TomoTherapy assumes no obligation to update or revise forward-looking statements in this release because of new information, future events or otherwise.

© 2009 TomoTherapy Incorporated. All rights reserved. The following marks as used herein the italicized or stylized text are among the trademarks, service marks or registered trademarks of TomoTherapy Incorporated in the United States and other countries: TomoTherapy, Tomo, TomoDirect, TomoHelical, TomoHD, TomoMobile, TQM, Hi · Art, and the TomoTherapy logo.

About the Author